FI871012A - Hybridinterferoner, deras anvaendning saosom laekemedel och mellanprodukter foer framstaellning av antikroppar och deras anvaendning samt foerfarande foer deras framstaellning. - Google Patents

Hybridinterferoner, deras anvaendning saosom laekemedel och mellanprodukter foer framstaellning av antikroppar och deras anvaendning samt foerfarande foer deras framstaellning. Download PDF

Info

Publication number
FI871012A
FI871012A FI871012A FI871012A FI871012A FI 871012 A FI871012 A FI 871012A FI 871012 A FI871012 A FI 871012A FI 871012 A FI871012 A FI 871012A FI 871012 A FI871012 A FI 871012A
Authority
FI
Finland
Prior art keywords
deras
novel
interferons
framstaellning
och
Prior art date
Application number
FI871012A
Other languages
English (en)
Other versions
FI871012A0 (fi
Inventor
Rudolf Hauptmann
Peter Swetly
Peter Meindl
Guenther Adolf
Edgar Falkner
Gerhard Bodo
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of FI871012A0 publication Critical patent/FI871012A0/fi
Publication of FI871012A publication Critical patent/FI871012A/fi
Priority to FI925631A priority Critical patent/FI925631A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Soft Magnetic Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI871012A 1986-03-10 1987-03-09 Hybridinterferoner, deras anvaendning saosom laekemedel och mellanprodukter foer framstaellning av antikroppar och deras anvaendning samt foerfarande foer deras framstaellning. FI871012A (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI925631A FI925631A (fi) 1986-03-10 1992-12-11 Monoklonala antikroppar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863607835 DE3607835A1 (de) 1986-03-10 1986-03-10 Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
FI871012A0 FI871012A0 (fi) 1987-03-09
FI871012A true FI871012A (fi) 1987-09-11

Family

ID=6295926

Family Applications (2)

Application Number Title Priority Date Filing Date
FI871012A FI871012A (fi) 1986-03-10 1987-03-09 Hybridinterferoner, deras anvaendning saosom laekemedel och mellanprodukter foer framstaellning av antikroppar och deras anvaendning samt foerfarande foer deras framstaellning.
FI925631A FI925631A (fi) 1986-03-10 1992-12-11 Monoklonala antikroppar

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI925631A FI925631A (fi) 1986-03-10 1992-12-11 Monoklonala antikroppar

Country Status (21)

Country Link
US (1) US4917887A (fi)
EP (1) EP0236920B1 (fi)
JP (1) JPS62282595A (fi)
KR (1) KR950008191B1 (fi)
AT (1) ATE81671T1 (fi)
AU (1) AU600702B2 (fi)
DD (2) DD276493A5 (fi)
DE (2) DE3607835A1 (fi)
DK (1) DK120387A (fi)
ES (1) ES2052502T3 (fi)
FI (2) FI871012A (fi)
GR (1) GR3006844T3 (fi)
HU (1) HU206896B (fi)
IE (2) IE60573B1 (fi)
IL (1) IL81832A0 (fi)
NO (1) NO870967L (fi)
NZ (1) NZ219549A (fi)
PH (1) PH27060A (fi)
PT (1) PT84427B (fi)
SU (1) SU1604164A3 (fi)
ZA (1) ZA871679B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
AT389318B (de) * 1987-10-22 1989-11-27 Boehringer Ingelheim Int Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
US5047231A (en) * 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
US5000973A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Nutritionally-balanced canine biscuits containing an inorganic pyrophosphate
US5000943A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Canine biscuits containing an inorganic pyrophosphate
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
US5000940A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Devices, compositions and the like having or containing an inorganic pyrophosphate
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
ES2378977T3 (es) * 1998-03-13 2012-04-19 Brown University Research Foundation Isoforma del canal de calcio del tipo N humano y usos de la misma
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
KR20040022244A (ko) * 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2003063573A2 (en) * 2001-11-09 2003-08-07 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX366124B (es) * 2013-03-15 2019-06-27 Janssen Biotech Inc Anticuerpos antagonistas del interferón alfa y omega.
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
JPH064673B2 (ja) * 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
AU1155083A (en) * 1982-01-19 1983-07-28 Cetus Corporation Multiclass hybrid interferons
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
ATE67786T1 (de) * 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
DE3428370A1 (de) * 1984-08-01 1986-02-13 Boehringer Ingelheim International GmbH, 6507 Ingelheim Interferon, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen
DE3574145D1 (en) * 1984-08-27 1989-12-14 Genentech Inc Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators

Also Published As

Publication number Publication date
HUT44074A (en) 1988-01-28
AU6978687A (en) 1987-09-17
GR3006844T3 (fi) 1993-06-30
DD276493A5 (de) 1990-02-28
FI925631A0 (fi) 1992-12-11
NZ219549A (en) 1990-07-26
DK120387D0 (da) 1987-03-09
KR950008191B1 (ko) 1995-07-26
US4917887A (en) 1990-04-17
IE870591L (en) 1987-09-10
ES2052502T3 (es) 1994-07-16
IL81832A0 (en) 1987-10-20
IE60573B1 (en) 1994-07-27
EP0236920B1 (de) 1992-10-21
HU206896B (en) 1993-01-28
PT84427A (de) 1987-04-01
ZA871679B (en) 1988-11-30
EP0236920A2 (de) 1987-09-16
DD266118A5 (de) 1989-03-22
NO870967L (no) 1987-09-11
EP0236920A3 (en) 1988-03-02
DK120387A (da) 1987-09-11
JPS62282595A (ja) 1987-12-08
NO870967D0 (no) 1987-03-09
SU1604164A3 (ru) 1990-10-30
ATE81671T1 (de) 1992-11-15
PH27060A (en) 1993-02-01
AU600702B2 (en) 1990-08-23
FI925631A (fi) 1992-12-11
KR870009020A (ko) 1987-10-22
DE3607835A1 (de) 1987-09-24
PT84427B (pt) 1989-10-04
IE940131L (en) 1987-09-10
FI871012A0 (fi) 1987-03-09
DE3782259D1 (de) 1992-11-26

Similar Documents

Publication Publication Date Title
FI871012A (fi) Hybridinterferoner, deras anvaendning saosom laekemedel och mellanprodukter foer framstaellning av antikroppar och deras anvaendning samt foerfarande foer deras framstaellning.
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
FI864427A0 (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
NO872988D0 (no) Pattedyr-interleukin-4.
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
NO169725C (no) Fremgangsmaate for fremstilling av et uglykosylert rekombinant humant immun-interferonprotein
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
PH31198A (en) Protein recognized by antibodies raised against native P28 of schitosoma mansoni.
Kawade et al. Characterization of rat monoclonal antibodies to mouse interferon-α and-β
DK193187D0 (da) Interferoninduceret humanprotein paa ren form, dets fremstilling og anvendlese
FI874273A0 (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
IL82720A0 (en) Recombinant polypeptide containing the amino acid sequence of the protein of feline leukemia virus,expression vehicles,plasmids coding for said protein,method for production thereof and pharmaceutical compositions

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH